Overview

Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting

Status:
Not yet recruiting

Trial end date:
2023-05-15

Target enrollment:
0

Participant gender:
All

Summary

The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Tanta University

Treatments:

Dexmedetomidine
Pregabalin

Criteria

Inclusion Criteria:

- CABG patients ≥ 65 years of age both genders American Society of Anesthesiologists
(ASA) physical status classification II or III planned for fast track developed
postoperative delirium (POD).

Exclusion Criteria:

- Patients who had history of psychiatric diseases; inability to communicate;

- previous history of POD; preoperative sick sinus syndrome, allergy/sensitivity to
pregabalin or dexmedetomidine, severe bradycardia (heart rate <50 beat per minute),
second-degree or above atrioventricular block without pacemaker; severe hepatic or
renal insufficiency.

- Previous cardiac or thoracic surgery, known diagnosis of depression or other major
psychiatric diseases, cognitive impairment or inability to cooperate with the study,
renal insufficiency, and history of substance abuse.